Expertise in
7
conditions

Dr. Lori Goldstein

Oncology
Fox Chase Cancer Center Medical Group Inc
333 Cottman Ave, 
Philadelphia, PA 
Expertise in
7
conditions
Fox Chase Cancer Center Medical Group Inc
333 Cottman Ave, 
Philadelphia, PA 

Overview

Lori Goldstein is an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Goldstein is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Specialist in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Fox Chase Cancer Center Medical Group Inc
333 Cottman Ave, Philadelphia, PA 19111
Other Locations
Temple University of the Commonwealth System of Higher Education
2450 W Hunting Park Ave, Philadelphia, PA 19129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

69 Total Publications

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 11, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology
Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology
Referral may be required

Fox Chase Cancer Center Medical Group Inc

333 Cottman Ave, 
Philadelphia, PA 
 (0.1 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hossein Borghaei is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology
Expertise in
18
conditions
Dr. Daniel Geynisman
Hematology | Oncology
Referral may be required

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (0.1 miles away)
215-728-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Geynisman is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Geynisman is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Expertise in
15
conditions
Dr. Elizabeth Plimack
Oncology
Expertise in
15
conditions
Dr. Elizabeth Plimack
Oncology
Referral may be required

Temple University Hospital-Jeanes Campus

7600 Central Ave, 
Philadelphia, PA 
 (0.3 miles away)
215-728-2500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Plimack is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Plimack is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Lori Goldstein

How do I make an appointment with Dr. Lori Goldstein?

You can book an appointment with Dr. Lori Goldstein by calling their office at 215-728-6900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lori Goldstein a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lori Goldstein is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lori Goldstein specialize in?

While Dr. Lori Goldstein is a Oncology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Lori Goldstein participate in research or clinical trials?

Yes. Dr. Lori Goldstein has published 69 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Lori Goldstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldstein's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile